Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether a concentrate containing both FVIII and von
Willebrand Factor (VWF) given at a high dose will induce immune tolerance in subjects who
have already experienced and failed ITI with VWF-free FVIII concentrates. The treatment on
this study is expected to last up to 33 months.
Phase:
N/A
Details
Lead Sponsor:
City of Hope Medical Center
Collaborators:
Biotest Pharmaceuticals Corporation Charta Fondazione Charta Foundation CSL Behring Grifols Biologicals Inc. Grifols Biologicals, LLC Grifols Therapeutics Inc. Grifols Therapeutics LLC